enGene Therapeutics
ENGN
30 hedge funds and large institutions have $228M invested in enGene Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
3.73% more ownership
Funds ownership: 73.83% → 77.55% (+3.7%)
0% more funds holding
Funds holding: 30 → 30 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
26% less capital invested
Capital invested by funds: $307M → $228M (-$79.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$12.9M |
| 2 |
VA
VR Adviser
New York
|
+$5.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.61M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
+$4.53M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.54M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.22M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.78M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.98M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.49M |
ENGN Hedge Fund Activity: Q3 2024 in Review
30 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q3 2024, worth a combined $228M — down 26% from $307M a quarter earlier.
Fund positioning in ENGN was balanced in Q3 2024: 6 funds opened new positions, 6 closed out, 10 added to existing stakes and 4 trimmed.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $12.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.54M sold.
- 30 institutional investors held enGene Therapeutics (ENGN) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $228M of enGene Therapeutics stock for Q3 2024, down 26% quarter-over-quarter.
- 6 funds opened new enGene Therapeutics positions in Q3 2024 and 6 closed out, a net change of 0 holders.
- The largest enGene Therapeutics buyer in Q3 2024 was Kynam Capital Management, an estimated $12.9M added.
- The largest enGene Therapeutics seller in Q3 2024 was Perceptive Advisors, an estimated $7.54M sold.
Based on aggregated 13F filings for Q3 2024.